An Observational Study of Patients With Chronic Liver Disease

Target PharmaSolutions

Status: Invitation-only

Conditions: Chronic Liver Disease; Cirrhosis

Treatments: Other: Observational

Study type: Observational

Funder types: Industry

Identifiers

NCT05744713

TARGET-LD

Details and patient eligibility

About

TARGET-Liver Disease (TARGET-LD) is an observational research study to conduct a comprehensive review of outcomes for patients with chronic liver disease (CLD).

Enrollment: 500,000 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

Disease Cohort

•Adult* patients at the time of enrollment with a diagnosis of CLD/cirrhosis by ICD-10 code in the EHR interface

Engaged Cohort

• Adult* patients diagnosed and managed for CLD/cirrhosis invited to participate
• Ability to provide written informed consent

Exclusion criteria

Disease Cohort

• Death
• Manual removal (sponsor or site request)
• No EHR interface encounter > 3 years.

Engaged Cohort

• Patient expressed desire to withdraw consent to complete PROs
• Failure to complete PROs within 24 weeks of initial invitation
• Greater than 24 months lapse of survey completion after baseline surveys completed
• Additionally, the criteria detailed for Disease Cohort apply to the Engaged Cohort.

Trial design

500,000 participants in 2 patient groups

Disease Cohort

Treatment:

Other: Observational

Engaged Cohort

Treatment:

Other: Observational